Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion de Jong

Showing results (11-20 of 193) with videos related to

Pageof 20
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2003
Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002Marion de Jong, Dik Kwekkeboom, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 3, 2009
Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapyCristina Müller, Thomas L Mindt, Marion de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2008
Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancerCristina Müller, Roger Schibli, Eric P Krenning, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 31, 2015
Radiopeptides for Imaging and Therapy: A Radiant FutureKristell L S Chatalic, Dik J Kwekkeboom, Marion de Jong
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)LuMark W Konijnenberg, Magda Bijster, Eric P Krenning, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapyMark Konijnenberg, Marleen Melis, Roelf Valkema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 30, 2013
"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targetingBerthold A Nock, Theodosia Maina, Eric P Krenning, et al.
Nuclear Medicine and Biology|August 21, 2007
Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneysCristina Müller, Roger Schibli, Flavio Forrer, et al.
Bioconjugate Chemistry|July 24, 2008
"Click-to-chelate": in vitro and in vivo comparison of a 99mTc(CO)3-labeled N(tau)-histidine folate derivative with its isostructural, clicked 1,2,3-triazole analogueThomas L Mindt, Cristina Müller, Marleen Melis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2008
SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolateCristina Müller, Flavio Forrer, Roger Schibli, et al.
Pageof 20

Showing results (11-20 of 193) with videos related to

Sort By:
Pageof 20
European Journal of Nuclear Medicine and Molecular Imaging|February 6, 2003
Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002Marion de Jong, Dik Kwekkeboom, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 3, 2009
Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapyCristina Müller, Thomas L Mindt, Marion de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2008
Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancerCristina Müller, Roger Schibli, Eric P Krenning, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 31, 2015
Radiopeptides for Imaging and Therapy: A Radiant FutureKristell L S Chatalic, Dik J Kwekkeboom, Marion de Jong
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 6, 2004
A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)LuMark W Konijnenberg, Magda Bijster, Eric P Krenning, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2007
Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapyMark Konijnenberg, Marleen Melis, Roelf Valkema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 30, 2013
"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targetingBerthold A Nock, Theodosia Maina, Eric P Krenning, et al.
Nuclear Medicine and Biology|August 21, 2007
Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneysCristina Müller, Roger Schibli, Flavio Forrer, et al.
Bioconjugate Chemistry|July 24, 2008
"Click-to-chelate": in vitro and in vivo comparison of a 99mTc(CO)3-labeled N(tau)-histidine folate derivative with its isostructural, clicked 1,2,3-triazole analogueThomas L Mindt, Cristina Müller, Marleen Melis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2008
SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolateCristina Müller, Flavio Forrer, Roger Schibli, et al.
Pageof 20